Folic acid reverses uric acid crystal-induced surface OAT1 internalization by inhibiting RhoA activity in uric acid nephropathy

Wu,Xinlin; Liu,Jianxiang; Zhang,Jianqing; Liu,Heng; Yan,Miansheng; Liang,Birong; Xie,Hongbo; Zhang,Shijun; Sun,Baoguo; Zhou,Houming

doi:10.3892/mmr.2016.4837

Folic acid reverses uric acid crystal-induced surface OAT1 internalization by inhibiting RhoA activity in uric acid nephropathy

Authors:
- Xinlin Wu
- Jianxiang Liu
- Jianqing Zhang
- Heng Liu
- Miansheng Yan
- Birong Liang
- Hongbo Xie
- Shijun Zhang
- Baoguo Sun
- Houming Zhou
View Affiliations

Affiliations: Department of Traditional Chinese Medicine, The First Affiliated Hospital, Sun Yat‑sen University, Guangzhou, Guangdong 510080, P.R. China, Key Laboratory of Medicinal Biotechnology, Guilin Medical University, Guilin, Guangxi 541004, P.R. China
Published online on: January 29, 2016 https://doi.org/10.3892/mmr.2016.4837
Pages: 2385-2392
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To investigate how organic anion transporter (OAT)-1 is involved in uric acid nephropathy (UAN), a rat model for UAN was established and the serum uric acid, blood urea nitrogen and serum creatinine levels were all measured, and observed to be increased. It was additionally identified that in UAN rats the surface OAT1 expression levels were reduced. By treating HEK cells with monosodium urate (MSU) crystals, it was observed that the cells exhibited a reduction in OAT1 levels. Furthermore, MSU crystals were observed to recruit Ras homolog family member A (RhoA), a small guanosine triphosphatase, to the membrane and activate it. Following RhoA activation, the OAT1 internalization rate was identified to be increased. The dominant‑negative RhoA N19 mutation was able to block MSU‑induced OAT1 internalization, indicating that the process was RhoA‑dependent. Finally, the results indicated that folic acid, a daily nutritional supplement, was capable of rescuing MSU‑induced nephropathy and OAT1 internalization. These observations indicated that uric acid crystals were able to reduce the OAT1 membrane distribution through activating RhoA, and that folic acid was capable of preventing MSU-induced OAT1 relocation by inhibiting the RhoA signaling pathway.

View Figures

View References

1	Klemp P, Stansfield SA, Castle B and Robertson MC: Gout is on the increase in New Zealand. Ann Rheum Dis. 56:22–26. 1997. View Article : Google Scholar : PubMed/NCBI
2	Arromdee E, Michet CJ, Crowson CS, O'Fallon WM and Gabriel SE: Epidemiology of gout: Is the incidence rising? J Rheumatol. 29:2403–2406. 2002.PubMed/NCBI
3	Li Y, Stamler J, Xiao Z, Folsom A, Tao S and Zhang H: Serum uric acid and its correlates in Chinese adult populations, urban and rural, of Beijing. The PRC-USA collaborative study in cardiovascular and cardiopulmonary epidemiology. Int J Epidemiol. 26:288–296. 1997. View Article : Google Scholar : PubMed/NCBI
4	Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J and Mazzali M: Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 41:1183–1190. 2003. View Article : Google Scholar : PubMed/NCBI
5	Tseng CH: Independent association of uric acid levels with peripheral arterial disease in Taiwanese patients with Type 2 diabetes. Diabet Med. 21:724–729. 2004. View Article : Google Scholar : PubMed/NCBI
6	Kai H, Kaneyuki M, Shihara M, Toyama Y, Mitsutake Y, Umei H, Kusaba K, Ueda T, Adachi H and Imaizumi T; MAPPY Study Investigators: Reduction in morning blood pressure is a key factor for ameliorating urinary albumin excretion in patients with morning hypertension irrespective of treatment regimen. Circ J. 77:1551–1557. 2013. View Article : Google Scholar : PubMed/NCBI
7	Sekine T, Cha SH and Endou H: The multispecific organic anion transporter (OAT) family. Pflugers Arch. 440:337–350. 2000. View Article : Google Scholar : PubMed/NCBI
8	Koepsell H: The SLC22 family with transporters of organic cations, anions and zwitterions. Mol Aspects Med. 34:413–435. 2013. View Article : Google Scholar : PubMed/NCBI
9	Sweeney DE, Vallon V, Rieg T, Wu W, Gallegos TF and Nigam SK: Functional maturation of drug transporters in the developing, neonatal, and postnatal kidney. Mol Pharmacol. 80:147–154. 2011. View Article : Google Scholar : PubMed/NCBI
10	Ulmius M, Johansson-Persson A, Krogh M, Olsson P and Önning G: An oat bran meal influences blood insulin levels and related gene sets in peripheral blood mononuclear cells of healthy subjects. Genes Nutr. 6:429–439. 2011. View Article : Google Scholar : PubMed/NCBI
11	Pritchard JB: Coupled transport of p-aminohippurate by rat kidney basolateral membrane vesicles. Am J Physiol. 255:F597–F604. 1988.PubMed/NCBI
12	Sweet DH, Wolff NA and Pritchard JB: Expression cloning and characterization of ROAT1. The basolateral organic anion transporter in rat kidney. J Biol Chem. 272:30088–30095. 1997. View Article : Google Scholar : PubMed/NCBI
13	Burckhardt G: Drug transport by organic anion transporters (OATs). Pharmacol Ther. 136:106–130. 2012. View Article : Google Scholar : PubMed/NCBI
14	Pavlova A, Sakurai H, Leclercq B, Beier DR, Yu AS and Nigam SK: Developmentally regulated expression of organic ion transporters NKT (OAT1), OCT1, NLT (OAT2), and Roct. Am J Physiol Renal Physiol. 278:F635–F643. 2000.PubMed/NCBI
15	VanWert AL, Gionfriddo MR and Sweet DH: Organic anion transporters: Discovery, pharmacology, regulation and roles in pathophysiology. Biopharm Drug Dispos. 31:1–71. 2010.
16	Kim S, Lee CH, Kang CM and Kim GH: Effects of increased uric acid intake on the abundance of urate-anion exchanger and organic anion transporter proteins in the rat kidney. Electrolyte Blood Press. 5:62–67. 2007. View Article : Google Scholar : PubMed/NCBI
17	Yarlagadda SG and Perazella MA: Drug-induced crystal nephropathy: An update. Expert Opin Drug Saf. 7:147–158. 2008. View Article : Google Scholar : PubMed/NCBI
18	Wu X, Liu L, Xie H, Liao J, Zhou X, Wan J, Yu K, Li J and Zhang Y: Tanshinone IIA prevents uric acid nephropathy in rats through NF-κB inhibition. Planta Med. 78:866–873. 2012. View Article : Google Scholar : PubMed/NCBI
19	Kim YI: Will mandatory folic acid fortification prevent or promote cancer? Am J Clin Nutr. 80:1123–1128. 2004.PubMed/NCBI
20	Choi SW and Mason JB: Folate status: Effects on pathways of colorectal carcinogenesis. J Nutr. 132(Suppl 8): S2413–S2418. 2002.
21	Lin SY, Lee WR, Su YF, Hsu SP, Lin HC, Ho PY, Hou TC, Chou YP, Kuo CT and Lee WS: Folic acid inhibits endothelial cell proliferation through activating the cSrc/ERK 2/NF-κB/p53 pathway mediated by folic acid receptor. Angiogenesis. 15:671–683. 2012. View Article : Google Scholar : PubMed/NCBI
22	Hou TC, Lin JJ, Wen HC, Chen LC, Hsu SP and Lee WS: Folic acid inhibits endothelial cell migration through inhibiting the RhoA activity mediated by activating the folic acid receptor/cSrc/p190RhoGAP-signaling pathway. Biochem Pharmacol. 85:376–384. 2013. View Article : Google Scholar
23	Fromme T and Klingenspor M: Rapid single step subcloning procedure by combined action of type II and type IIs endonucleases with ligase. J Biol Eng. 1:1–3. 2007. View Article : Google Scholar
24	Shi Y, Evans JE and Rock KL: Molecular identification of a danger signal that alerts the immune system to dying cells. Nature. 425:516–521. 2003. View Article : Google Scholar : PubMed/NCBI
25	Etienne-Manneville S and Hall A: Rho GTPases in cell biology. Nature. 420:629–635. 2002. View Article : Google Scholar : PubMed/NCBI